Teva Pharmaceutical Industries (NYSE:TEVA) has been assigned a $16.00 price objective by stock analysts at Piper Jaffray Companies in a research note issued to investors on Thursday. The brokerage currently has a “hold” rating on the stock. Piper Jaffray Companies’ price target indicates a potential upside of 1.91% from the company’s current price.
A number of other research analysts have also recently commented on TEVA. Oppenheimer restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday. Cantor Fitzgerald set a $10.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Thursday. Guggenheim initiated coverage on Teva Pharmaceutical Industries in a research report on Tuesday. They issued a “neutral” rating and a $16.00 price target on the stock. ValuEngine upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Tuesday, December 5th. Finally, Royal Bank of Canada set a $11.00 price target on Teva Pharmaceutical Industries and gave the stock a “sell” rating in a research report on Wednesday, November 29th. Seven investment analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $19.34.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded down $0.82 during trading on Thursday, reaching $15.70. The company’s stock had a trading volume of 30,494,500 shares, compared to its average volume of 15,888,267. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $38.31. The firm has a market cap of $16,784.32, a P/E ratio of 3.82 and a beta of 0.55. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.
A number of institutional investors have recently made changes to their positions in TEVA. Capital Research Global Investors grew its stake in Teva Pharmaceutical Industries by 13.8% in the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after purchasing an additional 9,260,426 shares during the period. Franklin Resources Inc. grew its stake in Teva Pharmaceutical Industries by 11.1% in the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after purchasing an additional 6,685,844 shares during the period. FMR LLC grew its stake in Teva Pharmaceutical Industries by 16.7% in the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after purchasing an additional 6,115,853 shares during the period. Macquarie Group Ltd. grew its stake in Teva Pharmaceutical Industries by 350.3% in the 3rd quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock valued at $77,587,000 after purchasing an additional 3,429,448 shares during the period. Finally, Capital World Investors grew its stake in Teva Pharmaceutical Industries by 41.9% in the 2nd quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after purchasing an additional 3,268,200 shares during the period. Institutional investors and hedge funds own 52.05% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/14/piper-jaffray-companies-analysts-give-teva-pharmaceutical-industries-teva-a-16-00-price-target.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.